Recommendations for benefit–risk assessment methodologies and visual representations
- 22 January 2016
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 25 (3) , 251-262
Abstract
Purpose: The purpose of this study is to draw on the practical experience from the PROTECT BR case studies and make recommendations regarding the application of a number of methodologies and visual representations for benefit–risk assessment.Methods: Eight case studies based on the benefit–risk balance of real medicines were used to test various methodologies that had been identified from the literature as having potential applications in benefit–risk assessment. Recommendations were drawn up based on the results of the case studies.Results: A general pathway through the case studies was evident, with various classes of methodologies having roles to play at different stages. Descriptive and quantitative frameworks were widely used throughout to structure problems, with other methods such as metrics, estimation techniques and elicitation techniques providing ways to incorporate technical or numerical data from various sources. Similarly, tree diagrams and effects tables were universally adopted, with other visualisations available to suit specific methodologies or tasks as required. Every assessment was found to follow five broad stages: (i) Planning, (ii) Evidence gathering and data preparation, (iii) Analysis, (iv) Exploration and (v) Conclusion and dissemination.Conclusions: Adopting formal, structured approaches to benefit–risk assessment was feasible in real‐world problems and facilitated clear, transparent decision‐making. Prior to this work, no extensive practical application and appraisal of methodologies had been conducted using real‐world case examples, leaving users with limited knowledge of their usefulness in the real world. The practical guidance provided here takes us one step closer to a harmonised approach to benefit–risk assessment from multiple perspectives. Copyright © 2016 John Wiley & Sons, Ltd.Keywords
Funding Information
- Innovative Medicines Initiative Joint Undertaking (115004)
This publication has 30 references indexed in Scilit:
- A stochastic multicriteria model for evidence‐based decision making in drug benefit‐risk analysisStatistics in Medicine, 2011
- Measures for Conducting Comparative Benefit: Risk AssessmentDrug Information Journal, 2008
- A survey on stochastic multicriteria acceptability analysis methodsJournal of Multi-Criteria Decision Analysis, 2007
- Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritisStatistics in Medicine, 2006
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004
- Communicating risks at the population level: application of population impact numbersBMJ, 2003
- Use of discrete choice experiments to elicit preferencesQuality and Safety in Health Care, 2001
- QALYs versus HYEs—what's right and what's wrong. A review of the controversyJournal of Health Economics, 1998
- Comparing Treatments Using Quality-Adjusted Survival: The Q-TWiST MethodThe American Statistician, 1995
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988